RedHill Biopharma Ltd. announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes’ U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment.
RedHill Biopharma Ltd. announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes’ U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment.